QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iida, I. Articles by Chiba, K. Search for Related Content PubMed PubMed Citation Articles by Iida, I. Articles by Chiba, K.

SHORT COMMUNICATION

CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9*2 AND CYP2C9*3) IN LORNOXICAM 5'-HYDROXYLATION

Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan (I.I., A.M., M.Ar. M.H., M.Ak., S.H.); and Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (K.K., K.C.)

The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5'-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9. The results of the baculovirus expression system showed that CYP2C9.3 gives higher K_m and lower V_max values for lornoxicam 5'-hydroxylation than does CYP2C9.1. In contrast, K_m and V_max values of CYP2C9.1 and CYP2C9.2 for the reaction were comparable. Lornoxicam 5'-hydroxylation was also determined in liver microsomes of 12 humans genotyped for the CYP2C9 gene (*1/*1, n = 7; *1/*2, n = 2; *1/*3, n = 2; *3/*3, n = 1). A sample genotyped as *3/*3 exhibited 8- to 50-fold lower intrinsic clearance for lornoxicam 5'-hydroxylation than did samples genotyped as *1/*1. However, the values for intrinsic clearance for *1/*3 were within the range of values exhibited by samples of *1/*1. In addition, no appreciable differences were observed in kinetic parameters for lornoxicam 5'-hydroxylation between *1/*1 and *1/*2. In conclusion, this study showed that lornoxicam 5'-hydroxylation via CYP2C9 was markedly decreased by the substitution of Ile359Leu (CYP2C9.3), whereas the effect of the substitution of Arg144Cys (CYP2C9.2) was nonexistent or negligible. Additional in vivo studies are required to confirm that individuals with homologous CYP2C9*3 allele exhibit impaired lornoxicam clearance.

This article has been cited by other articles:

				L. Wei, C. W. Locuson, and T. S. Tracy Polymorphic Variants of CYP2C9: Mechanisms Involved in Reduced Catalytic Activity Mol. Pharmacol., November 1, 2007; 72(5): 1280 - 1288. [Abstract] [Full Text] [PDF]

				A. D. Rodrigues IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME? Drug Metab. Dispos., November 1, 2005; 33(11): 1567 - 1575. [Abstract] [Full Text] [PDF]

				Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, D. Zhong, J. P. Fawcett, and H. Zhou ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS Drug Metab. Dispos., June 1, 2005; 33(6): 749 - 753. [Abstract] [Full Text] [PDF]